Levagen+ Efficacy Study on Diabetic Peripheral Neuropathy

Launched by RDC CLINICAL PTY LTD · Jun 17, 2025

Keywords

ClinConnect Summary

This clinical trial is studying whether a supplement called Levagen+ can help reduce the symptoms of diabetic peripheral neuropathy (DPN), which is a common condition causing nerve pain or numbness, usually in the feet and hands, for people with diabetes. The study aims to see if taking Levagen+ for 12 weeks improves these symptoms.

Adults aged 18 to 75 who have diabetes (type 1 or type 2) and are already using prescribed medications to manage their blood sugar may be eligible. They also need to have a certain level of nerve pain symptoms and be able to follow the study rules, like not changing their diet or exercise during the trial. Participants will take Levagen+ daily for 12 weeks, have remote check-ins every three weeks, and visit a local lab for blood tests. People with other serious health issues, certain medications, or lifestyle factors like smoking or heavy alcohol use may not qualify. This study is not yet recruiting participants, but if eligible, it offers a way to try a new supplement that might ease nerve pain related to diabetes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults aged 18-75 years.
• • Using prescribed glucose-lowering medications, including oral medications (stable dose for 3 months or more) and/or insulin for diabetes (type 1 or 2).
• • Scoring12 or more on the Self-reported Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS).
• • Able to provide informed consent.
• • Agree not to change current diet and/or exercise frequency or intensity during entire enrolment period.
• • Agree to not participate in another clinical trial during the study period.
• • Able to attend an ACL collection centre.
• Exclusion Criteria:
• • Peripheral neuropathy due to causes other than diabetes mellitus (e.g. nutritional deficiencies; hereditary sensory neuropathy; paraneoplastic diseases; advanced liver disease; kidney disease; hypothyroidism; prolonged phenytoin, warfarin or immunosuppressive drug use; active infection \[HIV, Lyme disease, Epstein-Barr virus, Hepatitis C, Shingles, Leprosy\]; autoimmune disease \[Sjogren syndrome, Lupus, Rheumatoid arthritis, Guillain-Barre syndrome\]; trauma / injury; toxins \[heavy metals, chemicals\]; antibiotics; or inflammatory conditions \[vasculitis\]).
• • Serious illness e.g., paraneoplastic diseases, advanced liver disease, kidney disease, hypothyroidism, mood disorders such as depression, anxiety or bipolar disorder, neurological disorders such as MS, or heart conditions, or peripheral vascular disease
• • Unstable illness e.g., diabetes and thyroid gland dysfunction, hypercholesterolemia
• • Current malignancy (excluding Basal Cell Carcinoma) or chemotherapy or radiotherapy treatment for malignancy within the previous 2 years.
• • Currently taking Coumadin (Warfarin), Heparin, Dalteparin, Enoxaparin or other anticoagulation therapy including low dose aspirin
• • Herbal medicines for pain relief including, but not limited to, medicinal cannabis, willow bark (Salix alba), Boswellia (Boswellia serrata) or turmeric/curcumin (Curcuma longa).
• • Active smokers, nicotine use or drug (prescription or illegal substances) abuse.
• • Chronic past and/or current alcohol use (\>14 alcoholic drinks per week)
• • Females attempting to conceive, pregnant or lactating
• • Allergic, sensitive or intolerant to any of the ingredients in active or placebo formula.
• • Difficulty swallowing capsules.
• • Participants who are currently participating in any other clinical trial or who have participated in any other clinical trial during the past 1 month.
• • Any condition which in the opinion of the investigator makes the participant unsuitable for inclusion.